NIH-PA Author Manuscript

NIH-PA Author Manuscript

NIH-PA Author Manuscript

The *trk*B Tyrosine Protein Kinase Is a Receptor for Brain-Derived Neurotrophic Factor and Neurotrophin-3

Rüdiger Klein[*], **Venkata Nanduri**[*], **Shuqian Jing**[*], **Fabienne Lamballe**[*], **Peter Tapley**[*], **Sherri Bryant**[*], **Carlos Cordon-Cardo**[*,†], **Kevin R. Jones**[‡], **Louis F. Reichardt**[‡], and **Mariano Barbacid**[*]

[*]Department of Molecular Biology, Bristol-Myers Squibb Pharmaceutical Research Institute, P.O. Box 4000, Princeton, New Jersey 08543-4000

[‡]Howard Hughes Medical Institute, University of California, San Francisco, San Francisco, California 94143

Summary

*trk*B is a tyrosine protein kinase gene highly related to *trk*, a proto-oncogene that encodes a receptor for nerve growth factor (NGF) and neurotrophin-3 (NT-3). *trk*B expression is confined to structures of the central and peripheral nervous systems, suggesting it also encodes a receptor for neurotrophic factors. Here we show that brain-derived neurotrophic factor (BDNF) and NT-3, but not NGF, can induce rapid phosphorylation on tyrosine of gp145^{trkB}, one of the receptors encoded by *trk*B. BDNF and NT-3 can induce DNA synthesis in quiescent NIH 3T3 cells that express gp145^{trkB}. Cotransfection of plasmids encoding gp145^{trkB} and BDNF or NT-3 leads to transformation of recipient NIH 3T3 cells. In these assays, BDNF elicits a response at least two orders of magnitude higher than NT-3. Finally, ^{125}I-NT-3 binds to NIH 3T3 cells expressing gp145^{trkB}; binding can be competed by NT-3 and BDNF but not by NGF. These findings indicate that gp145^{trkB} may function as a neurotrophic receptor for BDNF and NT-3.

Introduction

The *trk* proto-oncogene encodes a tyrosine protein kinase, gp140*trk*, that serves as a receptor for certain neurotrophic factors including nerve growth factor (NGF) (Hempstead et al., 1991; Kaplan et al., 1991; Klein et al., 1991) and the recently isolated neurotrophin-3 (NT-3) (Cordon-Cardo et al., 1991). At least two other mammalian genes highly related to the *trk* proto-oncogene have been identified (Barbacid et al., 1991). These genes, designated *trk*B and *trk*C, are expressed in multiple structures of the nervous system, suggesting that they may also encode neurogenic receptors (Klein et al., 1989, 1990a, 1990b; Middlemas et al., 1991; Lamballe et al., submitted).

The mammalian *trk*B locus has an intricate transcription pattern. At least six different *trk*B transcripts, ranging in size from 2.0 kb to 9.0 kb, have been identified in mouse brain (Klein et al., 1989, 1990a). Even more numerous transcripts have been detected in rat tissues (Middlemas et al., 1991). Preliminary sequence analysis of cDNA clones corresponding to some of these transcripts predicts the synthesis of multiple proteins. To date, two *trk*B gene products, designated gp145^{trkB} and gp95^{trkB}, have been identified (Klein et al., 1990a; Middlemas et al., 1991). The deduced amino acid sequence of gp145^{trkB} reveals the basic features characteristic of tyrosine protein kinase receptors. Comparison of the mouse

[†]On leave from: Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York 10021.

gp145^{trkB} sequence with that of the human gp140^{trk} receptor reveals a high degree of homology in their respective extracellular (51%) and catalytic kinase (88%) domains.

The *trk*B gene product gp95^{trkB} represents a new class of noncatalytic cell surface receptors (Klein et al., 1990a; Middlemas et al., 1991). cDNA sequence analysis predicts that amino acid residues 1 to 465 of gp95^{trkB} are identical to those of gpl45^{trkB}. These residues encompass the signal peptide, extracellular domain, transmembrane region, and the first 12 cytoplasmic residues. However, gp95^{trkB} has a very short cytoplasmic domain of 23 residues, of which the last 11 have no resemblance to any of the gpl45^{trkB} sequences. Analysis of rat cDNA clones predicts the existence of a second noncatalytic isoform of almost identical sequence to gp95^{trkB} except for its 9 carboxy-terminal residues (Middlemas et al., 1991).

In situ hybridization studies have indicated that *trk*B is expressed in numerous structures of the central and peripheral nervous systems (Klein et al., 1989, 1990b). During development, *trk*B expression can be first detected in 9.5-day-old embryos, a time when the central and peripheral nervous systems are in the process of differentiating into anatomically recognizable structures. In later-stage embryos, the pattern of *trk*B expression parallels the developing structures of the central and peripheral nervous systems (Klein et al., 1990b). In the adult brain, *trk*B mRNAs can be found in most structures, including the cortical layers, the thalamus, and the hippocampus (particularly the pyramidal cell layer), the lateral choroid plexus, and the ependymal lining of certain ventricles. A more restricted pattern of expression can be observed in the cerebellum, where only the Purkinje cell layer and the caudal peduncle have detectable levels of *trk*B expression (Klein et al., 1990b).

Subsequent studies utilizing probes specific for the various *trk*B transcripts have indicated that the catalytic (gp145^{trkB}) and noncatalytic (gp95^{trkB}) receptors are expressed in different structures (Klein et al., 1990a). Analysis of coronal sections of the adult mouse brain revealed gp145^{trkB}-coding transcripts in the cortical layers, the thalamus, and the hippocampus, therefore suggesting a primary role for gp145^{trkB} in neurons. In contrast, the noncatalytic gp95^{trkB} receptor may not be expressed in neurons since transcripts encoding gp95^{trkB} have been found in the choroid plexus and the ependymal cell layer of certain ventricles (Klein et al., 1990a). This pattern of expression raises the possibility that gp95^{trkB} may play a role in the transport and/or clearance of the putative *trk*B ligand. The localization of transcripts encoding the various *trk*B receptors in the peripheral nervous system remains to be determined.

The recent identification of gp140^{trk} as a functional receptor for NGF and NT-3 (Cordon-Cardo et al., 1991; Hempstead et al., 1991; Kaplan et al., 1991; Klein et al., 1991; Nebreda et al., 1991) has raised the possibility that at least some of the *trk*B products may serve as receptors for neurotrophic factors. NGF and NT-3 are members of a highly related family of peptides that also includes brain-derived neurotrophic factor (BDNF) (Barde et al., 1982; Leibrock et al., 1989) and the recently isolated neurotrophin-4 (NT-4) (Hallböök et al., 1991). As mature factors, these proteins share close to 60% amino acid identity, including their six cysteine residues that presumably confer on them related tertiary structures (Hallböök et al., 1991; Hohn et al., 1990; Jones and Reichardt, 1990; Maisonpierre et al., 1990a; Rosenthal et al., 1990). These factors, particularly BDNF and NT-3, are expressed in a wide variety of neural structures, many of which also contain *trk*B transcripts (Ernfors et al., 1990b; Hofer et al., 1990; Maisonpierre et al., 1990a, 1990b; Phillips et al., 1990). We undertook the present studies to examine whether any of these neurotrophic factors may serve as ligands for gp145^{trkB}, a tyrosine protein kinase receptor encoded by the mammalian *trk*B gene.

Results

Coexpression of *trk*B with BDNF or NT-3 Induces Cell Transformation

We have recently shown that NGF, and to a lesser extent NT-3, is a mitogen for NIH 3T3 cells expressing gp140^{trk} receptors (Cordon-Cardo et al., 1991). Moreover, NIH 3T3 cells become morphologically transformed when they express the *trk* proto-oncogene in the presence of exogenous NGF. Cotransfection of expression plasmids encoding the *trk* proto-oncogene and NGF or NT-3 also led to the morphological transformation of NIH 3T3 cells in a dose-dependent manner (Cordon-Cardo et al., 1991). These results suggest that transformation of NIH 3T3 cells can be used as an experimental assay to investigate the ligand–receptor relationships between other *trk*-related genes and the NGF family of neurotrophic molecules.

To test this hypothesis, we cotransfected NIH 3T3 cells with Moloney murine sarcoma virus long terminal repeat-driven mammalian expression plasmids (see Experimental Procedures) encoding gp145^{trk}B (pFRK44) and each of the three neurotrophic factors, NGF (pLTRSNGF), BDNF (pLL42), and NT-3 (pLL43) (Table 1). As illustrated in Figure 1, cotransfection of saturating amounts of pFRK44 DNA (2 μg) with serial dilutions of pLL42 DNA resulted in the efficient transformation of NIH 3T3 cells. Quantitative analysis of these cotransfection assays indicated that BDNF can transform NIH 3T3 cells with an efficiency of 4×10^4 ffu per μg of pLL42 DNA, a transforming activity about one order of magnitude lower than that observed with *trk* oncogenes isolated from human tumors (Barbacid et al., 1991). The transforming activity of BDNF is entirely dependent on the expression of gp145^{trk}B receptors, since pLL42 DNA failed to induce any detectable morphological transformation when transfected alone into NIH 3T3 cells (Table 1).

Cotransfection of pFRK44 (*trk*B) and pLL43 (NT-3) DNAs also resulted in morphological transformation of the recipient NIH 3T3 cells, albeit with a 200-fold lower transformation efficiency (Table 1). Coexpression of pFRK44 and pLTRSNGF DNAs did not lead to detectable morphological transformation (Table 1). This result is in agreement with our previous report that ^{125}I-labeled NGF does not bind to NIH 3T3 cells expressing the gp145^{trk}B kinase (Klein et al., 1991). Next, we performed similar experiments in which NIH 3T3 cells were cotransfected with saturating amounts of each of the plasmids encoding the neurotrophic factors in the presence of various amounts of gp145^{trk}B-coding pFRK44 DNA. As illustrated in Table 2, pFRK44 DNA was able to transform the recipient NIH 3T3 cells only in the presence of the BDNF- and NT-3-coding plasmids, pLL42 and pLL43, respectively. Quantitative analysis revealed higher levels (50- to 100 fold) of transforming activity when pFRK44 was cotransfected in the presence of BDNF (pLL42) than when cotransfected with NT-3 (pLL43) (Table 2).

Phosphorylation of gp145^{trk}B Receptors by BDNF and NT-3

Recent studies have shown that NGF and NT-3, but not BDNF, induce the rapid phosphorylation of gpl40^{trk} on tyrosine residues (Cordon-Cardo et al., 1991; Kaplan et al., 1991; Klein et al., 1991). To examine whether BDNF and/or NT-3 could induce a similar response with the gp145^{trk}B kinase, we incubated Z52-17 cells, a NIH 3T3–derived cell line transfected with pFRK44 DNA, with each of the neurotrophic factors NGF, BDNF, and NT-3. BDNF and NT-3 were derived from Sf9 insect cells infected with recombinant baculoviruses or from COS cells transfected with cytomegalovirus/SV40-derived BDNF and NT-3 expression vectors (see Experimental Procedures). As shown in Figure 2, BDNF and NT-3 stimulated the rapid phosphorylation of tyrosine residues in gp145^{trk}B receptors regardless of whether they were synthesized in mammalian (Figure 2B) or insect (Figure 2C) cells. In contrast, neither NGF nor control supernatants from COS or Sf9 cells induced detectable phosphorylating activity.

Next, we investigated the extent of phosphorylation of gp145^{trkB} receptors expressed in Z82-41 cells, a transformed cell line generated by cotransfection of trkB and BDNF DNAs. As shown in Figure 2D, these cells expressed constitutively phosphorylated gp145^{trkB} receptors. The extent of phosphorylation of these receptors in the absence of ligand was at least comparable to that of gp145^{trkB} expressed in Z52-17 cells in the presence of saturating amounts (50 ng/ml) of BDNF. These results indicate that NIH 3T3 cells transformed by cotransfection of pFRK44 and pLL42 DNAs may owe their phenotype to the constitutive activation of the gp145^{trkB} receptor kinase by an autocrine loop. In addition to gp145^{trkB}, Z82-41 cells contain a second molecular species constitutively phosphorylated on tyrosine residues, and this species is likely to correspond to partially glycosylated gp145^{trkB} precursors (Figure 2D). These precursors do not become phosphorylated as a response to exogenously added ligands, suggesting that they are not located in the cell membrane (Figure 2D). Therefore, their constitutive phosphorylation in Z82-41 cells raises the possibility that BDNF can recognize trkB receptors intracellularly before they are completely processed and properly anchored in the plasma membrane. Whether this interaction elicits signal transduction remains to be determined.

Mitogenic Activity of BDNF and NT-3

We have previously shown that gp140^{trk} receptors mediate the mitogenic activity of their cognate NGF and NT-3 ligands on NIH 3T3 cells (Cordon-Cardo et al., 1991). To examine whether BDNF and NT-3 have similar activity on cells expressing gp145^{trkB} receptors, we incubated quiescent Z52-17 cells with partially purified BDNF and NT-3 factors derived from Sf9 insect cells infected with the corresponding recombinant baculoviruses. As controls, we utilized E25-48 cells, a NIH 3T3 cell line that expresses gp140^{trk} receptors (Klein et al., 1991). As shown in Figure 3A, NGF, and to a lesser extent NT-3, stimulated the incorporation of ^{3}H-labeled thymidine in these E25-48 cells. Neither BDNF nor control supernatants obtained from Sf9 cells infected with wild-type baculoviruses had any significant effect. When the same experiment was performed on Z52-l7 cells, both BDNF and NT-3 induced DNA synthesis in a dose-dependent manner (Figure 3B). Quiescent Z52-17 cells could not be stimulated either by NGF or by control supernatants (Figure 3B). Similar results were obtained when we replaced these partially purified baculovirus-expressed factors with crude preparations derived from BDNF- and NT-3-transfected COS cells. Finally, the parental NIH 3T3 cells did not respond to any of the neurotrophic factor preparations used in these experiments (data not shown).

To determine the percentage of Z52-17 cells responsive to BDNF and NT-3, we conducted DNA synthesis assays in the presence of 5-bromodeoxyuridine (BrdUrd) (Table 3). As illustrated in Figures 4A and 4B, stimulation of quiescent NIH 3T3 and Z52-17 cells with 20% calf serum induced more than 80% of these cells to enter S phase within 24 hr. Neither insulin nor NGF elicited significant DNA synthesis (Figures 4C–4F). In contrast, supernatants derived from COS cells transfected with BDNF and NT-3 expression plasmids induced 64% and 47% of Z52-17 cells to enter S phase, respectively (Figures 4H and 4J; Table 3). As negative controls, neither BDNF- nor NT-3-containing COS cell–derived supernatants had significant mitogenic activity on the parental NIH 3T3 cells (Figures 4G and 4I). Immunocytochemistry studies revealed that about 80% of Z52-17 cells expressed detectable levels of gp145^{trkB} receptors (data not shown). Therefore, the percentage of Z52-17 cells responding to BDNF is similar to that responding to 20% calf serum.

The more limited mitogenic effects of NT-3 on NIH 3T3 cells expressing gp145^{trkB} receptors (Table 3) is in agreement with the results obtained in transformation assays. Purified preparations (50 ng/ml) of baculovirus-derived BDNF and NT-3 also had mitogenic effects, although they appeared to be somewhat less efficient. Whether this difference is due to their processing in Sf9 insect cells or to loss of activity during purification remains to be determined.

Binding of ^{125}I-Labeled NT-3 to gp145^{trk}B

The above results suggest that gpl45^{trk}B is a functional receptor for BDNF and NT-3. However, formal proof of a direct interaction between these molecules and the gp145^{trk}B kinase requires binding studies. To this end, we iodinated purified BDNF and NT-3 proteins isolated from baculovirus-infected Sf9 cells as indicated in Experimental Procedures. NT-3 was efficiently iodinated using the Bolton-Hunter reagent, which primarily labels lysine residues. Other iodination methods that lead to the specific labeling of tyrosine residues yielded less efficient results. NGF became equally well labeled with either method. Unfortunately, parallel efforts to iodinate the BDNF protein have been unsuccessful thus far. Therefore, we had to limit our direct binding studies to the NT-3 protein.

As shown in Figure 5, incubation of NIH 3T3 cells expressing gp140^{trk} (E25-48 cells) or gp145^{trk}B (B35-41 and Z52-17 cells) receptors with 1 nM ^{125}I-labeled NT-3 at 4 °C resulted in its efficient binding. Moreover, a significant fraction of the observed ^{125}I-labeled NT-3 binding could be readily competed by a 75-fold excess of unlabeled NT-3. In contrast, the parental NIH 3T3 cells exhibited very limited binding (less than 20% of that bound to E25-48, B35-41, or Z52-17 cells), none of which could be competed with a similar excess of unlabeled neurotrophic factor (Figure 5).

To overcome the unavailability of ^{125}I-labeled BDNF, we utilized competitive binding assays to determine whether BDNF may also bind to gpl40^{trk} and/or gpl45^{trk}B receptors. In agreement with our previous studies, NGF but not BDNF could displace binding of ^{125}I-labeled NT-3 to gp140^{trk}-expressing E25-48 cells (data not shown). These results add further support to the concept that BDNF does not interact with gp140^{trk} receptors. In contrast, BDNF readily displaced ^{125}I-labeled NT-3 from binding to gp145^{trk}B-expressing B35-41 cells (Figure 6). Moreover, BDNF was more effective in inhibiting ^{125}I-labeled NT-3 binding than unlabeled NT-3. Similar results were obtained with Z52-17 cells (data not shown). These observations indicate that BDNF may bind to gp145^{trk}B receptors with higher affinity than NT-3. Finally, NGF failed to displace ^{125}I-labeled NT-3 from binding to B35-41 cells (Figure 6), a result in agreement with our previous observations that ^{125}I-labeled NGF does not bind to cells expressing the gp145^{trk}B kinase (Klein et al., 1991).

Discussion

Transfection of NIH 3T3 cells with expression plasmids encoding gpl40^{trk} and its cognate ligands NGF and NT-3 results in transformation of the recipient cells (Cordon-Cardo et al., 1991). In the present studies, we have taken advantage of the mitogenic properties of the *trk* family of receptors to establish a functional ligand-receptor relationship between gp145^{trk}B and the neurotrophic factors BDNF and NT-3. We have demonstrated that constitutive expression of either BDNF or NT-3 in NIH 3T3 cells expressing the gp145^{trk}B kinase induces their morphological transformation. These transformation assays may prove useful to identify receptors for novel neurotrophic factors such as the recently isolated neurotrophin-4 (Hallböök et al., 1991). Moreover, they may help to identify the ligands of orphan neurogenic receptors such as the members of the *elkleck* family of tyrosine kinases (Letwin et al., 1988; Lindberg and Hunter, 1990; Lai and Lemke, 1991).

The identification of the gp145^{trk}B tyrosine kinase as a receptor for BDNF is supported by additional experimental evidence including the following: first, the induction of DNA synthesis by BDNF in quiescent NIH 3T3 cells expressing gp145^{trk}B receptors but not in their parental NIH 3T3 cells; second, the rapid phosphorylation on tyrosine residues of gp145^{trk}B molecules in cells exposed to BDNF; third, the constitutive tyrosine phosphorylation of gp145^{trk}B in cells coexpressing BDNF; and fourth, the efficient displacement of ^{125}I-labeled NT-3 from binding

to cells expressing gp145^{trk}B receptors. These results, taken together, firmly establish gp145^{trk}B as a functional receptor for BDNF.

In addition, gpl45^{trk}B is a receptor for NT-3. ^{125}I-labeled NT-3 binds efficiently to cells expressing gp145^{trk}B and induces its rapid phosphorylation on tyrosine residues. Moreover, the interaction of NT-3 with gpl45^{trk}B receptors has functional relevance since NT-3 can induce quiescent cells expressing gp145^{trk}B to enter S phase. However, the mitogenic activity of NT-3 on these cells appears to be more limited than that of BDNF since NT-3 exhibits 100- to 200-fold lower transforming activity when coexpressed with gpl45^{trk}B receptors. It could be argued that some of these differences may reflect less efficient expression of NT-3 in NIH 3T3 cells. However, we have recently shown that coexpression of NT-3 with *trk*C receptors induces the transformation of NIH 3T3 cells with an efficiency comparable to that of BDNF when cotransfected with gp145^{trk}B (Lamballe et al., submitted). Therefore, NT-3 is likely to mediate its biological responses through *trk*B as well as *trk*C receptors.

Each of the members of the NGF family of neurotrophins binds to the previously identified low affinity NGF receptor, gp80^{LNGFR} (Rodriguez-Tébar and Barde, 1988; Ernfors et al., 1990a; Hallböök et al., 1991). However, we have shown that NIH 3T3 cells do not express these receptors (Klein et al., 1991). Therefore, the mitogenic properties of BDNF and NT-3 reported in this study are likely to be mediated solely by gp145^{trk}B receptors. Our results, however, do not exclude the possibility that gp145^{trk}B may form complexes eitherwith gp80^{LNGFR} (Hempstead et al., 1991) or with other molecules to mediate the neurotrophic effects of BDNF and NT-3. Whether such multireceptor complexes exist and whether they modulate the neurotrophic activities of BDNF and NT-3 are interesting possibilities that should be explored.

The *trk*B gene is expressed in most structures of the peripheral and central nervous systems of the developing mouse embryo (Klein et al., 1989, 1990b). In the adult, available information regarding *trk*B expression is limited to the dorsal region of the cerebrum and certain areas of the cerebellum (Klein et al., 1990a, 1990b). In situ hybridization analysis conducted with probes specific for the various *trk*B transcripts has indicated that gp145^{trk}B receptors are primarily expressed in the cerebral cortex, hippocampus, and thalamus. Other structures such as the choroid plexus and the ependymal layer of the ventricles contain transcripts encoding the noncatalytic gp95^{trk}B protein (Klein et al., 1990a). In addition, *trk*B transcripts have been identified in a subset of sensory neurons that are known to respond to BDNF and NT-3. BDNF transcripts are also widely distributed in the adult brain (Ernfors et al., 1990b; Hofer et al., 1990; Maisonpierre et al., 1990a; Phillips et al., 1990). The highest levels of expression have been observed in the hippocampus (both pyramidal and granular neurons), cortex, amygdala, and the thalamic and hypothalamic nuclei. In the cerebellum, BDNF appears to be expressed in the internal granular layer (Hofer et al., 1990), whereas *trk*B transcripts are most prominent in the Purkinje cell layer (Klein et al., 1990b). On the other hand, NT-3 is expressed in a wide variety of tissues (Hohn et al., 1990; Maisonpierre et al., 1990a; Rosenthal et al., 1990). Whether in some of these tissues NT-3 interacts with receptors other than those encoded by *trk*B and *trk*C (Lamballe et al., submitted) remains to be determined.

The biological properties of BDNF appear to be as diverse as its pattern of expression. For instance, BDNF promotes the survival and differentiation of developing neurons of the dorsal root ganglion (Lindsay et al., 1985; Kalcheim et al., 1987). In addition, BDNF stimulates the survival as well as the differentiation of septal cholinergic neurons, which are known to degenerate in Alzheimer's disease (Alderson et al., 1990; Knüsel et al., 1991). BDNF also promotes the survival of dopaminergic neurons of the substantia nigra and appears to protect them against selective destruction by 1-methyl-4-phenylpyridinium, a chemical known to cause Parkinson's disease in humans (Hyman et al., 1991; Knüsel et al., 1991). In contrast,

NT-3 appears to have a more limited range of action since it supports the survival of sensory and sympathetic but not of cholinergic or dopaminergic neurons (Hohn et al., 1990; Maisonpierre et al., 1990a; Rosenthal et al., 1990). The identification of the gp145^{trk}B tyrosine kinase as a functional receptor for BDNF and NT-3 should make it possible to identify the primary cellular targets of this neurotrophic factor and help to elucidate its role in the normal brain as well as its potential involvement in neurodegenerative diseases such as Alzheimer's and Parkinson's diseases.

Experimental Procedures

Cells and Expression Plasmids

Cells, including NIH 3T3 (Jainchill et al., 1969) B35-41 and E25-48 (Klein et al., 1991), Z52-17, and Z82-41 cells, were grown in Dulbecco's modified Eagle's medium (DMEM) containing 10% calf serum. Z52-17 cells were obtained by transfecting NIH 3T3 cells with pFRK44, a pMEX*neo*-derived expression plasmid (Martin-Zanca et al., 1989) containing the mouse *trk*B cDNA encoding the catalytic gp145^{trk}B protein (Klein et al., 1989). Z82-41 cells were generated by cotransfection of NIH 3T3 cells with pFRK44 and pLL42 DNAs. pLL42 is a pMEX-derived expression plasmid (Martin-Zanca et al., 1989) that contains an 850 bp insert encoding the human prepro-BDNF(Jones and Reichardt, 1990). pLL43 is a similar pMEX-derived plasmid that contains a 930 bp insert corresponding to the human prepro-NT-3 (Jones and Reichardt, 1990). pLTRSNGF is a pBR322-based expression plasmid (Izant and Weintraub, 1984) containing a 960 bp insert encoding the mouse prepro-NGF flanked by the Moloney murine sarcoma virus long terminal repeat and the SV40 polyadenylation signal (Clegg and Reichardt, unpublished data). pVN1 and pVN2 expression plasmids were generated by amplifying the corresponding inserts of pLL42 and pLL43 and subcloning them into pCM7B, a COS cell expression vector that contains the cytomegalovirus enhancer/promoter element and the SV40 polyadenylation signal (Seed, 1987). Gene transfer assays in NIH 3T3 cells were performed by the calcium phosphate precipitation technique, as previously described (Graham and van der Eb, 1973).

Neurotrophic Factors

Murine 2.5S NGF was purchased from Upstate Biotechnology, Inc. BDNF and NT-3 were purified from supernatants of Sf9 insect cells infected with recombinant baculoviruses pAcS27 (BDNF) and pAcS28 (NT-3), as recently described (Cordon-Cardo et al., 1991). Purified BDNF and NT-3 were approximately 95% pure as judged by Coomassie blue–stained SDS–polyacrylamide gels, and amino acid sequencing showed that NT-3 was properly processed at the amino terminus (Cordon-Cardo et al., 1991). Transient expression of BDNF and NT-3 using a COS cell expression system was performed essentially as described (Seed and Aruffo, 1987). Approximately 5×10^6 COS cells were transfected with 10 μg of pVNl (BDNF) and pVN2 (NT-3) DNAs and 24 hr later split at a 1:2 dilution. After an additional 24 hr incubation in DMEM containing 10% calf serum, cells were placed in serum-free DMEM containing 5 μg/ml insulin and transferrin (Sigma). Cell-free supernatants were harvested 4 days later.

Immunoblotting

Detection of phosphorylated tyrosine residues in gp140^{trk} and gp145^{trk}B receptors was carried out by Western blot analysis as previously described (Klein et al., 1991). Cell extracts were immunoprecipitated with a rabbit polyclonal antiserum raised against a peptide corresponding to the 14 carboxy-terminal amino acid residues of the human *trk* proto-oncogene product (Martin-Zanca et al., 1989) or against the mouse *trk*B tyrosine kinase domain expressed in bacteria (Klein et al., 1990a). Mouse anti-phosphotyrosine monoclonal antibody 4G10 (UBI) was then used as primary antibody after transfer of the immunoprecipitated proteins onto

nitrocellulose filters. Filters were subsequently incubated with rabbit anti-mouse IgG (Dako) before probing with ^{125}I-labeled protein A.

DNA Synthesis

Induction of DNA synthesis in quiescent cells following stimulation by neurotrophic factors was measured by incorporation of ^{3}H-labeled thymidine into newly synthesized DNA as previously described (Cordon-Cardo et al., 1991). The percentage of cells entering S phase was determined by immunofluorescence assays on cells incubated in the presence of BrdUrd (Cordon-Cardo et al., 1991). Fixed cells were incubated with a 1:50 dilution of a mouse monoclonal anti-BrdUrd antibody (Becton Dickinson), washed with PBS, and subsequently incubated with a 1:50 dilution of a donkey polyclonal anti-mouse IgG antiserum conjugated with Texas red (Amersham).

Binding Assays

Purified baculovirus-expressed NT-3 was radioiodinated using ^{125}I-labeled Bolton-Hunter reagent (2 mCi per reaction; 4000 Ci/mmol; Du Pont) as previously described (Rodriguez-Tébar and Barde, 1988). The labeled protein was separated by gel filtration through a G-25 column (medium) preequilibrated with 50 mM sodium acetate (pH 4.0) containing 150 mM NaCl and 0.5% (wt/vol) BSA and was eluted with the same buffer at a flow rate of 0.2–0.25 ml/min. Fractions of ~0.5 ml were collected, and the radioactivity in each fraction was determined in an Atomlab 100 gamma counter. The fractions containing the protein (3–4 fractions) were pooled. Analysis of the purity of ^{125}I-labeled NT-3 by 20% SDS–polyacrylamide gel electrophoresis did not reveal other significant protein species present in the NT-3 preparation.

Competition binding assays were done essentially as previously described (Jing et al., 1990; Klein et al., 1991). Cells (2×10^5 per sample) were preincubated with various concentrations (0.5 ng/ml to 1 µg/ml) of unlabeled factors at 4°C for 1 hr. The same volume of ^{125}I-labeled NT-3 was added to each sample to reach a final concentration of 5 ng/ml. Cells were further incubated at 4 °C for 2 hr, washed four times with ice-cold DMEM containing 0.1% BSA, and lysed in 100 µl of 1 N NaOH, and radioactivity was counted in a G5500 gamma counter (Beckman).

Acknowledgments

References

Alderson RF, Alterman AL, Barde Y-A, Lindsay RM. Brain-derived neurotrophic factor increases survival and differentiated functions of rat septal cholinergic neurons in culture. Neuron 1990;5:297–306. [PubMed: 2169269]

Barbacid M, Lamballe F, Pulido D, Klein R. The *trk* family of tyrosine protein kinase receptors. Biochim Biophys Acta Rev Cancer. 1991in press

Barde Y-A, Edgar D, Thoenen H. Purification of a new neurotrophic factor from mammalian brain. EMBO J 1982;1:549–553. [PubMed: 7188352]

Cordon-Cardo C, Tapley P, Jing S, Nanduri V, O'Rourke E, Lamballe F, Kovary K, Klein R, Jones KR, Reichardt LF, Barbacid M. The *trk* tyrosine protein kinase mediates the mitogenic properties of nerve growth factor and neurotrophin-3. Cell 1991;66:173–l83. [PubMed: 1649007]

Ernfors P, Ibáñez CF, Ebenndal T, Olson L, Persson H. Molecular cloning and neurotrophic activities of a protein with structural similarities to nerve growth factor: developmental and topographical expression in the brain. Proc Natl Acad Sci USA 1990a;87:5454–5458. [PubMed: 2164684]

Ernfors P, Wetmore C, Olson L, Persson H. Identification of cells in rat brain and peripheral tissues expressing mRNA for members of the nerve growth factor family. Neuron 1990b;5:511–526. [PubMed: 2206535]

Graham FL, van der Eb AJ. A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology 1973;52:456–467. [PubMed: 4705382]

Hallböök F, Ibáñez CF, Persson H. Evolutionary studies of the nerve growth factor family reveal a novel member abundantly expressed in Xenopus ovary. Neuron 1991;6:845–858. [PubMed: 2025430]

Hempstead BL, Martin-Zanca D, Kaplan DR, Parada LF, Chao MV. High-affinity NGF binding requires coexpression of the *trk* proto-oncogene and the low-affinity NGF receptor. Nature 1991;350:678–683. [PubMed: 1850821]

Hofer M, Paglisui SR, Hohn A, Leibrock J, Barde Y-A. Regional distribution of brain-derived neurotrophic factor mRNA in the adult mouse brain. EMBO J 1990;9:2459–2464. [PubMed: 2369898]

Hohn A, Leibrock J, Bailey K, Barde Y-A. Identification and characterization of a novel member of the nerve growth factor/brain-derived neurotrophic factor family. Nature 1990;344:339–341. [PubMed: 2314473]

Hyman C, Hofer M, Barde Y-A, Juhasz M, Yancopoulos GD, Squinto SP, Lindsay RM. BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra. Nature 1991;350:230–232. [PubMed: 2005978]

Izant JG, Weintraub H. Inhibition of thymidine kinase gene expression by anti-sense RNA: a molecular approach to genetic analysis. Cell 1984;36:1007–1015. [PubMed: 6323013]

Jainchill JL, Aaronson SA, Todaro GJ. Murine sarcoma and leukemia viruses: assay using clonal lines of contact-inhibited mouse cells. J Virol 1969;4:549–553. [PubMed: 4311790]

Jing S, Spencer T, Miller K, Hopkins C, Trowbridge IS. Role of the human transferrin receptor cytoplasmic domain in endocytosis: localization of a specific signal sequence for internalization. J Cell Biol 1990;110:283–294. [PubMed: 2298808]

Jones KR, Reichardt LF. Molecular cloning of a human gene that is a member of the nerve growth factor family. Proc Natl Acad Sci USA 1990;87:8060–8064. [PubMed: 2236018]

Kalcheim C, Barde Y-A, Thoenen H, Le Douarin NM. *In vivo* effect of brain-derived neurotrophic factor on the survival of developing dorsal root ganglion cells. EMBO J 1987;6:2871–2873. [PubMed: 3691474]

Kaplan DR, Martin-Zanca D, Parada LF. Tyrosine phosphorylation and tyrosine kinase activity of the *trk* proto-oncogene product induced by NGF. Nature 1991;350:158–160. [PubMed: 1706478]

Klein R, Parada LF, Coulier F, Barbacid M. *trk*B, a novel tyrosine protein kinase receptor expressed during mouse neural development. EMBO J 1989;8:3701–3709. [PubMed: 2555172]

Klein R, Conway D, Parada LF, Barbacid M. The *trk*B tyrosine protein kinase gene codes for a second neurogenic receptor that lacks the catalytic kinase domain. Cell 1990a;61:647–656. [PubMed: 2160854]

Klein R, Martin-Zanca D, Barbacid M, Parada LF. Expression of the tyrosine kinase receptor gene *trk*B is confined to the murine embryonic and adult nervous system. Development 1990b;109:845–850. [PubMed: 2171894]

Klein R, Jing S, Nanduri V, O'Rourke E, Barbacid M. The *trk* proto-oncogene encodes a receptor for nerve growth factor. Cell 1991;65:189–197. [PubMed: 1849459]

Knüsel B, Winslow JW, Rosenthal A, Burton LE, Seid DP, Nikolics K, Hefti F. Promotion of central cholinergic and dopaminergic neuron differentiation by brain-derived neurotrophic factor but not neurotrophin-3. Proc Natl Acad Sci USA 1991;88:961–965. [PubMed: 1992488]

Lai C, Lemke G. An extended family of protein-tyrosine kinase genes differentially expressed in the vertebrate nervous system. Neuron 1991;6:691–704. [PubMed: 2025425]

Leibrock J, Lottspeich F, Hohn A, Hofer M, Hengerer B, Masiakowski P, Thoenen H, Barde Y-A. Molecular cloning and expression of brain-derived neurotrophic factor. Nature 1989;341:149–152. [PubMed: 2779653]

Letwin K, Yee S-P, Pawson T. Novel protein-tyrosine kinase cDNAs related to *fpslfes* and *eph* cloned using anti-phosphotyrosine antibody. Oncogene 1988;3:621–678. [PubMed: 2485255]

Lindberg RA, Hunter T. cDNA cloning and characterization of *eck*, an epithelial cell receptor protein-tyrosine kinase in the *ephlelk* family of protein kinases. Mol Cell Biol 1990;10:6316–6324. [PubMed: 2174105]

Lindsay RM, Thoenen H, Barde Y-A. Placode and neural crest-derived sensory neurons are responsive at early developmental stages to brain-derived neurotrophic factor. Dev Biol 1985;112:319–328. [PubMed: 4076545]

Maisonpierre PC, Belluscio L, Squinto S, Ip NY, Furth ME, Lindsay RM, Yancopoulos GD. Neurotrophin-3: a neurotrophic factor related to NGF and BDNF. Science 1990a;247:1446–1451. [PubMed: 2321006]

Maisonpierre PC, Belluscio L, Friedman B, Adlerson RF, Wiegand SJ, Furth ME, Lindsay RM, Yancopoulos GD. NT-3, BDNF, and NGF in the developing rat nervous system: parallel as well as reciprocal patterns of expression. Neuron 1990b;5:501–509. [PubMed: 1688327]

Martin-Zanca D, Oskam R, Mitra G, Copeland T, Barbacid M. Molecular and biochemical characterization of the human *trk* proto-oncogene. Mol Cell Biol 1989;9:24–33. [PubMed: 2927393]

Middlemas DS, Lindberg RA, Hunter T. *trk*B, a neural receptor protein-tyrosine kinase: evidence for a full-length and two truncated receptors. Mol Cell Biol 1991;11:143–153. [PubMed: 1846020]

Nebreda AR, Martin-Zanca D, Kaplan DR, Parada LF, Santos E. Induction by NGF of meiotic maturation of *Xenopus* oocytes expressing the *trk* protooncogene product. Science 1991;252:558–561. [PubMed: 1850550]

Phillips HS, Hains JM, Laramee GR, Rosenthal A, Winslow JW. Widespread expression of BDNF but not NT-3 by target areas of basal forebrain cholinergic neurons. Science 1990;250:290–294. [PubMed: 1688328]

Rodriguez-Tébar A, Barde Y-A. Binding characteristics of brain-derived neurotrophic factor to its receptors on neurons from the chick embryo. J Neurosci 1988;8:3337–3342. [PubMed: 2845018]

Rosenthal A, Goeddel DV, Nguyen T, Lewis M, Shih A, Laramee GR, Nikolics K, Winslow JW. Primary structure and biological activity of a novel human neurotrophic factor. Neuron 1990;4:767–773. [PubMed: 2344409]

Seed B. An LFA-3 cDNA encodes a phospholipid-linked membrane protein homologous to its receptor CD2. Nature 1987;329:840–842. [PubMed: 3313052]

Seed B, Aruffo A. Molecular cloning of the CD2 antigen, the T cell erythrocyte receptor, by a rapid immunoselection procedure. Proc Natl Acad Sci USA 1987;84:3365–3369. [PubMed: 2437578]

Figure 1. Transformation of NIH 3T3 Cells by Cotransfection of *trk*B with BDNF or NT-3
NIH 3T3 cells were transfected with saturating amounts (2 μg) of the *trk*B kinase expression plasmid pFRK44 in either the absence or presence of various amounts (2 μg to 2 ng) of the pLL42 (BDNF) or pLL43 (NT-3) expression plasmids. As controls, pLL42 and pLL43 DNAs (2 μg) were transfected in the absence of pFRK44 DNA. Foci of transformed cells were counted under the microscope 12 days after transfection (Table 2) and the plates subsequently stained with Giemsa.

Figure 2. BDNF and NT-3 Stimulate Phosphorylation of Tyrosine Residues in the *trk*B Tyrosine Kinase Receptor gpl45*trkB*

(A) gp140*trk*-expressing E25-48 cells incubated in the absence (lane a) or presence (lane b) of 50 ng/ml NGF.

(B) gp145*trkB*-expressing Z52-17 cells incubated with a 1:10 dilution of supernatant from mock-transfected COS cells (lane a), 50 ng/ml NGF (lane b), a 1:10 dilution of supernatant from COS cells transfected with pVN1 (BDNF) (lane c), or a 1:10 dilution of supernatant derived from COS cells transfected with pVN2 (NT-3) (lane d).

(C) gp145*trkB*-expressing Z52-17 cells incubated with supernatant from Sf9 cells infected with wild-type baculovirus (lane a) or 50 ng/ml NGF (lane b), 50 ng/ml baculovirus-derived BDNF (lane c), or 50 ng/ml baculovirus-derived NT-3 (lane d).

(D) Lane a, Z52-17 cells incubated with supernatant from Sf9 cells infected with wild-type baculovirus. Lane c, Z52-17 cells incubated with 50 ng/ml baculovirus-derived BDNF. Lane e, Z82-41 cells transformed by cotransfection of pFRK44 (*trk*B) and pLL42 (BDNF) DNAs in the absence of ligand.

All incubations were performed for 10 min at 37°C. Cells were lysed and incubated with rabbit polyclonal antibodies elicited against gp140*trk* (Martin-Zanca et al., 1989) (A) or gp145*trkB* (Klein et al., 1990a) (B–D). Immunoprecipitates were analyzed by 8% SDS–polyacrylamide gel electrophoresis, transferred to nitrocellulose filters, and blotted with the anti-phosphotyrosine monoclonal antibody 4G10 (UBI) as described in Experimental Procedures. Filters were exposed to Kodak X-Omat film for 24 hr at −70°C with the help of an intensifying screen. The migration of gp140*trk* and gp145*trkB* receptors is indicated by arrows. The open arrowhead indicates the migration of a phosphorylated precursor of gp145*trkB*.

Figure 3. Stimulation of ^{3}H-Labeled Thymidine Incorporation by BDNF and NT-3
Quiescent gp140^{trk}-expressing E25-48 cells (A) and gp145^{trk}B-expressing Z52-17 cells (B) were incubated in DMEM containing 5 μg/ml insulin and the indicated amounts of NGF (open circles), baculovirus-derived BDNF(filled circles), baculovirus-derived NT-3 (open squares), or supernatant from wild-type baculovirus-infected Sf9 insect cells (filled squares). Incorporation of ^{3}H-labeled thymidine into DNA was measured in duplicate samples 22 hr after stimulation as described in Experimental Procedures. Values are not corrected for DNA synthesis in untreated resting cultures.

Figure 4. Induction of DNA Synthesis by BDNF and NT-3
Quiescent NIH 3T3 (left-hand panels) and gpl45^{trk}B-expressing Z52-17 cells (right-hand panels) were incubated in the presence of 100 μM BrdUrd plus 5 μg/ml insulin and the following additions: 20% calf serum (A, B), no additions(C, D), 50 ng/ml NGF(E, F), a1:10 dilution of supernatants derived from COS cells expressing BDNF (G, H), or a 1:10 dilution of supernatants derived from COS cells expressing NT-3 (I, J). Cells were fixed after 24 hr and analyzed for immunofluorescence using a mouse anti-BrdUrd monoclonal antibody and donkey anti-mouse IgG conjugated with Texas red. Final magnification 290 x.

Figure 5. Binding of NT-3 to Cells Expressing *trk* and *trk*B Tyrosine Protein Kinases
Cells, including parental NIH 3T3 cells and NIH 3T3 cells expressing the human *trk* (E25-48) and mouse *trk*B (B35-41, Z52-17) proto-oncogenes, were incubated with 1 nM ^{125}I-labeled NT-3 at 4°C for 2 hr in the absence (hatched bars) or presence (filled bars) of 75 nM purified unlabeled NT-3. Unbound NT-3 was removed at the end of the incubation, and the radioactivity associated with the cells was measured as described in Experimental Procedures. Results are expressed as the mean of duplicate samples.

Figure 6. BDNF Competes with ^{125}I-Labeled NT-3 for Binding to gp145^{trk}B Receptors
B35-41 cells were preincubated with unlabeled NGF (open circles), purified NT-3 (open
squares), or purified BDNF (filled circles) at 4°C for 1 hr. ^{125}I-labeled NT-3 was added to a
final concentration of 5 ng/ml, and the cells were incubated for an additional 2 hr. The
percentage of ^{125}I-labeled NT-3 bound to the cells was determined as described in
Experimental Procedures. Nonspecific binding to control NIH 3T3 cells (≤ 10%) was
subtracted from the results presented. The data shown here represent the average of two
separate experiments with duplicate samples.

Table 1

Transformation of NIH 3T3 cells by Cotransfection of pFRK44, an Expression Plasmid Encoding gp145^{trk}B, with Expression Plasmids Encoding BDNF, NT-3, and NGF

Cotransfection of pFRK44 DNA^a with			
Neurotrophic Factor	**Plasmid^b**	**DNA (ng)**	**Transforming Activity (Foci per 1.5 × 10^5 Cells)**
—	—	—	0
BDNF	pLL42	2000	TMTC^c
		200	TMTC
		20	>500
		2	80
NT-3	pLL43	2000	200
		200	44
		20	6
		2	0
NGF	pLTRSNGF	2000	0
		200	0

^{a}Two micrograms of pFRK44 DNA was used in each case.

^{b}Transfection of 2 μg of either pLTRSNGF, pLL42, or pLL43 alone did not induce morphological transformation of NIH 3T3 cells.

^{c}TMTC, too many to count.

Table 2

Transformation of NIH 3T3 Cells by Cotransfection of Expression Plasmids Encoding BDNF, NT-3, and NGF with Varying Amounts of pFRK44 DNA

Cotransfected DNA		
Neutrophic Factor DNA[a]	**pFRK44 DNA (ng)**	**Transforming Activity (Foci per 1.5×10^5 Cells)**
pLL42 (BDNF)	100	TMTC[b]
	10	>350
	1	120
	0.1	9
pLL43 (NT-3)	100	189
	10	16
	1	3
pLTRSNGF (NGF)	1000	0
	100	0

[a]One microgram of either pLTRSNGF, pLL42, or pLL43 DNA was used in each case.

[b]TMTC, too many to count.

Table 3

Mitogenic Activity of BDNF and NT-3 on gp145^{trk}B-Expressing Z52-17 Cells

| Additions[a] | BrdUrd Incorporation | | | |
| | NIH 3T3 Cells | | Z52-17 Cells | |
	Positive/Total	Percentage Positive	Positive/Total	Percentage Positive
None	16/421	3.8%	41/372	10.9%
20% Calf serum	525/630	83.3%	532/602	88.3%
BDNF (COS cells)	30/254	11.8%	186/289	64.3%
BDNF (Sf9 cells)	20/396	5.0%	151/447	33.7%
NT-3 (COS cells)	31/349	8.8%	97/206	47.0%
NT-3 (Sf9 cells)	19/393	4.8%	186/576	32.2%
NGF	13/226	5.7%	39/280	13.9%

[a]All samples contained 5 μg/ml insulin. BDNF and NT-3 derived from COS cells were used as 1:10 dilutions of cell free supernatants. BDNF and NT-3 purified from Sf9 cells were used at final concentrations of 50 ng/ml. NGF (UBI) was also used at a final concentration of 50 ng/ml.